| Category |
Field Label |
Field Display Name |
Explanation |
|
ExtractDate |
ExtractDate |
Date the data is extracted |
|
Latitude |
Latitude |
|
|
Longitude |
Longitude |
|
|
EpiWeek |
EpiWeek |
Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/ |
|
Week |
Week |
Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/ |
|
WeeklyBoosterVaccines |
Weekly Booster Vaccines |
Amount of boosters given during week |
| Vaccine Brand |
AstraZeneca |
AstraZeneca |
|
| Janssen |
Janssen |
|
| Moderna |
Moderna |
|
| Pfizer |
Pfizer |
|
| Additional Doses by Brand |
AD_AstraZeneca |
AdditionalDoses AstraZeneca |
|
| AD_Janssen |
AdditionalDoses Janssen |
|
| AD_Moderna |
AdditionalDoses Moderna |
|
| AD_Pfizer |
AdditionalDoses Pfizer |
|
| Immunocompromised Doses by Brand |
ID_AstraZeneca |
ImmunocompromisedDoses AstraZeneca |
|
| ID_Janssen |
ImmunocompromisedDoses Janssen |
|
| ID_Moderna |
ImmunocompromisedDoses Moderna |
|
| ID_Pfizer |
ImmunocompromisedDoses Pfizer |
|
| Gender |
Male |
Male |
|
| Female |
Female |
|
| Not Assigned |
NA |
|
| Age Group Additional Dose |
AD_Age0to9 |
AdditionalDose Age5to11 |
Additional Dose Age 5 to 11 |
| AD_Age10to19 |
AdditionalDose Age12to19 |
Additional Dose Age 12 to 19 |
| AD_Age20to29 |
AdditionalDose Age20to29 |
Additional Dose Age 20 to 29 |
| AD_Age30to39 |
AdditionalDose Age30to39 |
Additional Dose Age 30 to 39 |
| AD_Age40to49 |
AdditionalDose Age40to49 |
Additional Dose Age 40 to 49 |
| AD_Age50to59 |
AdditionalDose Age50to59 |
Additional Dose Age 50 to 59 |
| AD_Age60to69 |
AdditionalDose Age60to69 |
Additional Dose Age 60 to 69 |
| AD_Age70to79 |
AdditionalDose Age70to79 |
Additional Dose Age 70 to 79 |
| AD_Age80_ |
AdditionalDose Age80+ |
Additional Dose Age 80+ |
| AD_NA |
AdditionalDose NotAssigned |
Additional Dose Not Assigned To Age Group |
| Age Group Additional Dose Cumulative |
AD_Age0to9_Cum |
AdditionalDose Cumulative Age5to11 |
Additional Dose Cumulative Age 5 to 11 |
| AD_Age10to19_Cum |
AdditionalDose Cumulative Age12to19 |
Additional Dose Cumulative Age 12 to 19 |
| AD_Age20to29_Cum |
AdditionalDose Cumulative Age20to29 |
Additional Dose Cumulative Age 20 to 29 |
| AD_Age30to39_Cum |
AdditionalDose Cumulative Age30to39 |
Additional Dose Cumulative Age 30 to 39 |
| AD_Age40to49_Cum |
AdditionalDose Cumulative Age40to49 |
Additional Dose Cumulative Age 40 to 49 |
| AD_Age50to59_Cum |
AdditionalDose Cumulative Age50to59 |
Additional Dose Cumulative Age 50 to 59 |
| AD_Age60to69_Cum |
AdditionalDose Cumulative Age60to69 |
Additional Dose Age 60 to 69 |
| AD_Age70to79_Cum |
AdditionalDose Cumulative Age70to79 |
Additional Dose Age 70 to 79 |
| AD_Age80__Cum |
AdditionalDose Cumulative Age80+ |
Additional Dose Cumulative Age 80+ |
| AD_NA_Cum |
AdditionalDose Cumulative Not Assigned |
Additional Dose Cumulative Not Assigned To Age Group |
| Age Group Immunocompromised Dose |
ID_Age0to9 |
ImmunocompromisedDoses Age5to11 |
Immunocompromised Dose Age 5 to 11 |
| ID_Age10to19 |
ImmunocompromisedDoses Age12to19 |
Immunocompromised Dose Age 12 to 19 |
| ID_Age20to29 |
ImmunocompromisedDoses Age20to29 |
Immunocompromised Dose Age 20 to 29 |
| ID_Age30to39 |
ImmunocompromisedDoses Age30to39 |
Immunocompromised Dose Age 30 to 39 |
| ID_Age40to49 |
ImmunocompromisedDoses Age40to49 |
Immunocompromised Dose Age 40 to 49 |
| ID_Age50to59 |
ImmunocompromisedDoses Age50to59 |
Immunocompromised Dose Age 50 to 59 |
| ID_Age60to69 |
ImmunocompromisedDoses Age60to69 |
Immunocompromised Dose Age 60 to 69 |
| ID_Age70to79 |
ImmunocompromisedDoses Age70to79 |
Immunocompromised Dose Age 70 to 79 |
| ID_Age80_ |
ImmunocompromisedDoses Age80+ |
Immunocompromised Dose Age 80+ |
| ID_NA |
ImmunocompromisedDoses Not Assigned |
Immunocompromised Dose Not Assigned To Age Group |
| Age Group Immunocompromised Dose Cumulative |
ID_Age0to9_Cum |
ImmunocompromisedDoses Cumulative Age5to11 |
Immunocompromised Dose Cumulative Age 5 to 11 |
| ID_Age10to19_Cum |
ImmunocompromisedDoses Cumulative Age12to19 |
Immunocompromised Dose Cumulative Age 12 to 19 |
| ID_Age20to29_Cum |
ImmunocompromisedDoses Cumulative Age20to29 |
Immunocompromised Dose Cumulative Age 20 to 29 |
| ID_Age30to39_Cum |
ImmunocompromisedDoses Cumulative Age30to39 |
Immunocompromised Dose Cumulative Age 30 to 39 |
| ID_Age40to49_Cum |
ImmunocompromisedDoses Cumulative Age40to49 |
Immunocompromised Dose Cumulative Age 40 to 49 |
| ID_Age50to59_Cum |
ImmunocompromisedDoses Cumulative Age50to59 |
Immunocompromised Dose Cumulative Age 50 to 59 |
| ID_Age60to69_Cum |
ImmunocompromisedDoses Cumulative Age60to69 |
Immunocompromised Dose Age 60 to 69 |
| ID_Age70to79_Cum |
ImmunocompromisedDoses Cumulative Age70to79 |
Immunocompromised Dose Age 70 to 79 |
| ID_Age80__Cum |
ImmunocompromisedDoses Cumulative Age80+ |
Immunocompromised Dose Cumulative Age 80+ |
| ID_NA_Cum |
ImmunocompromisedDoses Cumulative NotAssigned |
Immunocompromised Dose Cumulative Not Assigned To Age Group |
| Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Each Age Group |
BoosterPer_Age0to9 |
IDandADTotal % of Population Age5to11 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 5 to 11 |
| BoosterPer_Age10to19 |
IDandADTotal % of Population Age12to19 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 12 to 19 |
| BoosterPer_Age20to29 |
IDandADTotal % of Population Age20to30 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 20 to 29 |
| BoosterPer_Age30to39 |
IDandADTotal % of Population Age30to40 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 30 to 39 |
| BoosterPer_Age40to49 |
IDandADTotal % of Population Age40to50 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 40 to 49 |
| BoosterPer_Age50to59 |
IDandADTotal % of Population Age50to60 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 50 to 59 |
| BoosterPer_Age60to69 |
IDandADTotal % of Population Age60to70 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 60 to 69 |
| BoosterPer_Age70to79 |
IDandADTotal % of Population Age70to80 |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 70 to 79 |
| BoosterPer_Age80_ |
IDandADTotal % of Population Age80+ |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 80+ |
| BoosterPer_NA |
IDandADTotal % of Population Not Assigned |
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population Not Assigned To Age Group |